Royal Bank of Canada set a $30.00 target price on Bausch Health Companies (NYSE:BHC) in a research report sent to investors on Monday, The Fly reports. The firm currently has a hold rating on the stock.
Several other analysts have also weighed in on the stock. ValuEngine lowered shares of Bausch Health Companies from a hold rating to a sell rating in a research note on Friday, September 7th. Cantor Fitzgerald restated a buy rating and set a $32.00 price target on shares of Bausch Health Companies in a research report on Wednesday, September 12th. Piper Jaffray Companies upgraded shares of Bausch Health Companies from an underweight rating to a neutral rating and upped their price target for the stock from $16.00 to $19.00 in a research report on Thursday, September 13th. Deutsche Bank set a $30.00 price target on shares of Bausch Health Companies and gave the stock a buy rating in a research report on Wednesday, September 12th. Finally, HC Wainwright restated a hold rating and set a $20.00 price target on shares of Bausch Health Companies in a research report on Friday, August 31st. Three research analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $26.89.
BHC stock opened at $26.49 on Monday. The company has a debt-to-equity ratio of 6.99, a current ratio of 1.14 and a quick ratio of 0.89. Bausch Health Companies has a 1-year low of $10.94 and a 1-year high of $28.45. The firm has a market cap of $8.97 billion, a price-to-earnings ratio of 6.92, a price-to-earnings-growth ratio of 0.37 and a beta of -0.48.
Bausch Health Companies (NYSE:BHC) last released its earnings results on Tuesday, August 7th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.12. Bausch Health Companies had a negative net margin of 20.60% and a positive return on equity of 27.83%. The firm had revenue of $2.13 billion during the quarter, compared to analyst estimates of $2.05 billion. Equities research analysts predict that Bausch Health Companies will post 3.47 earnings per share for the current fiscal year.
In other news, CFO Paul Herendeen purchased 10,000 shares of the stock in a transaction dated Friday, September 14th. The stock was acquired at an average price of $22.61 per share, for a total transaction of $226,100.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph C. Papa purchased 30,000 shares of the stock in a transaction dated Friday, September 14th. The shares were purchased at an average price of $22.32 per share, with a total value of $669,600.00. The disclosure for this purchase can be found here. Insiders have bought 165,000 shares of company stock valued at $3,890,700 in the last 90 days. Insiders own 11.54% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in BHC. Private Management Group Inc. bought a new position in Bausch Health Companies in the 2nd quarter valued at about $28,474,000. Tobam bought a new position in Bausch Health Companies in the 2nd quarter valued at about $13,886,000. Van ECK Associates Corp bought a new position in Bausch Health Companies in the 2nd quarter valued at about $11,494,000. Marshall Wace LLP bought a new position in Bausch Health Companies in the 2nd quarter valued at about $2,974,000. Finally, Point View Wealth Management Inc. bought a new position in Bausch Health Companies in the 2nd quarter valued at about $1,132,000. Institutional investors and hedge funds own 43.16% of the company’s stock.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Read More: How Do I Invest in Dividend Stocks
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.